Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report

作者：Wen Dong, Anli Dai, Zhijun Wu, Jiangtao Wang, Tao Wu, Yangfeng Du, Wei Tian, Jiang Zheng, Yan Zhang, Hongming Wang, Juan Cai, Susu Dong, Yan Zhou, Siyan Li, Zemin Xiao · 发表于：Frontiers in Immunology · 年份：2024 · DOI：10.3389/fimmu.2024.1371379 · 被引用次数：7 · 研究领域：Chromatin Remodeling and Cancer、Peptidase Inhibition and Analysis、Neuroendocrine Tumor Research Advances

SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT) is a devastating subtype of thoracic tumor with SMARCA4 inactivation and is characterized by rapid progression, poor prognosis, and high risk of postoperative recurrence. However, effective treatments for SMARCA4-dUT are lacking. Herein, we describe a patient with SMARCA4-dUT who exhibited an impressive response to the anti-programmed cell death protein-1 (PD-1) antibody (tislelizumab) in combination with conventional chemotherapy (etoposide and cisplatin). To the best of our knowledge, this is the first case of SMARCA4-dUT treated with chemotherapy, comprising etoposide and cisplatin, combined with anti-PD-1 inhibitors. Immunotherapy combined with etoposide and cisplatin may be a promising strategy to treat SMARCA4-dUT.